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ABSTRACT
Periodontal diseases, such as chronic periodontitis, share common inflammatory risk factors with other
systemic and chronic inflammatory disorders. Mucosal tissues, such as oral epithelia, are exposed to
environmental stressors, such as tobacco and oral bacteria, that might be involved in promoting a
systemic inflammatory state. Conversely, chronic disorders can also affect oral health. This review will
summarize recent evidence for the interrelationship between chronic periodontitis and other prevalent
chronic diseases such as cardiovascular diseases, diabetes, cancer and chronic respiratory diseases. The
association with pregnancy is also included due to possible obstetric complications. We will focus on
inflammatory cytokines such as TNF-alpha, IL-1, and IL-6, because they have been shown to be
increased in patients with chronic periodontitis, in patients with chronic systemic diseases, and in
patients with both chronic periodontitis and other chronic diseases. Therefore, an imbalance towards a
proinflammatory immune response could underline a bidirectional link between chronic periodontitis
and other chronic diseases. Finally, we highlight that a close coordination between dental and other
health professionals could promote oral health and prevent or ameliorate other chronic diseases.
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Introduction
Periodontal disease contributes significantly to the global bur-
den of oral diseases and shares common risk factors with
several chronic diseases. Recently, the World Health
Organization (WHO) highlighted the importance of strength-
ening the control of periodontal disease worldwide [1,2].
According to the WHO, chronic noncommunicable diseases,
including cardiovascular diseases, cancer, chronic respiratory
diseases, and diabetes, remain the leading causes, about 70%,
of death globally [3]. In addition, periodontal disease is one of
the most important oral diseases contributing to the global
burden of chronic diseases and therefore represents a major
public health problem [4]. In the present review, we will first
summarize the current classification of periodontal diseases,
and lately, we will focus the discussion on chronic period-
ontitis and cytokines in the context of common systemic
chronic inflammatory diseases.
Classification of periodontal diseases
Periodontal disease is a broad term for the spectrum of inflam-
matory diseases affecting the periodontium which comprises a
set of structures that support the teeth: gingiva, cementum,
periodontal ligament, and alveolar bone. In the 1999
classification system for periodontal diseases and conditions,
over 40 different gingival diseases were listed, that were either
dental-plaque induced or not associated with dental plaque
[5]. In addition, other major categories of destructive period-
ontal diseases were listed and periodontitis can also be a
manifestation of systemic diseases. An abbreviated version of
the 1999 classification of periodontal diseases and conditions
is shown in Table 1. Chronic periodontitis refers to the pro-
gression of the disease over time without treatment while
aggressive periodontitis shows rapid attachment loss and
bone destruction, and possible familial aggregation of disease.
According to that consensus, both are subcategorized in local
or generalized forms, depending on the percentage of tooth
affected sites (above or below 30%) and regarding the severity
of attachment loss (slight: 1 or 2 mm, moderate: 3 or 4 mm;
severe ≥5 mm) [5,6]. The distinction between chronic and
aggressive periodontitis is also based on several clinical fea-
tures, namely age of onset, rates of progression, patterns of
destruction, signs of inflammation, and relative amounts of
plaque, and calculus [7]. However, the features of chronic
periodontitis have been partially updated in 2014 by the
American Academy of Periodontology (AAP) who have also
announced that an update would commence in 2017 [8]. This
AAP task force report addressed three specific areas of con-
cern with the current classification: attachment level, chronic
CONTACT Elsa Maria Cardoso cardoso.elsamaria@fcsaude.ubi.pt CICS-UBI, Health Sciences Research Centre, Faculty of Health Sciences, University of Beira
Interior, Av. Infante D. Henrique, Covilhã 6200-506, Portugal
POSTGRADUATE MEDICINE, 2018
https://doi.org/10.1080/00325481.2018.1396876
© 2017 Informa UK Limited, trading as Taylor & Francis Group
D
ow
nl
oa
de
d 
by
 [b
-o
n: 
Bi
bli
ote
ca
 do
 co
nh
ec
im
en
to 
on
lin
e I
PG
] a
t 0
5:4
9 0
9 N
ov
em
be
r 2
01
7 
versus aggressive periodontitis, and localized versus general-
ized periodontitis [8]. Accordingly, diagnosis of periodontitis is
based on multiple clinical and radiographic parameters
(Table 2), all of which may not be required. In general, patients
would have periodontitis when one or more sites had inflam-
mation (bleeding on probing, BOP), radiographic bone loss,
and increased probing depth (>3 mm) or clinical attachment
loss (CAL ≥1 mm) [8].
Patients with gingival recession or on periodontal mainte-
nance therapy could present attachment loss, probing depth
≤3 mm, but with no signs of inflammation (no bleeding on
probing). These patients should be diagnosed with a healthy
but reduced periodontium [8]. However, if inflammation
(bleeding on probing) is present, the diagnosis should be a
reduced periodontium with inflammation, i.e. gingivitis.
However, in patients with probing depth >3 mm and with
inflammation, the diagnosis should be periodontitis with
severity according to guidelines shown in Table 2 [8]. This
report recognized some features already published in 1999
consensus report that would help to differentiate chronic
versus aggressive periodontitis. However, the clinician should
base diagnostic decisions based on the patient history, clinical
and radiographic signs (see ref 8). Regarding generalized
chronic periodontic, AAP task force preferred the percentage
of 30% affected teeth, instead of affected sites as an extent
descriptor [8]. Nevertheless, as mentioned above, a compre-
hensive update is planned for the current year (2017).
Chronic inflammation and cytokines in chronic
periodontitis
Chronic inflammation is a complex biological process that
occurs in response to infection and/or other triggers and
leads to tissue injury [9]. Chronic periodontitis is a periodontal
disease characterized by both dysbiosis of oral microbiota and
proinflammatory events involving both cells and mediators
from innate and adaptive immunity [10]. These events lead
to chronic inflammation of periodontal soft and hard tissues
sharing many features with other chronic inflammatory dis-
eases [11,12]. Chronic inflammation is driven by various med-
iators, of which an important part is attributed to the
interactions within cytokine networks. While proinflammatory
cytokines, including IL-1α, IL-1β, TNF-α, IL-6, and IL-17 contri-
bute to acute and chronic inflammation and tissue injury, a
second group with antagonist effects is formed by cytokines
such as IL-10 [13].
Chronic periodontitis is characterized by deregulated inflam-
matory interactions, involving both innate and adaptive
responses, that lead to a chronic inflammation in periodontal
tissues [14]. As other mucosal surfaces, the periodontal epithe-
lium is located at the interface between outside body environ-
ment and inside underlying connective tissue (Figure 1). From
outside, it is firmly established that the principal trigger of
Table 1. Abbreviated version of classification of periodontal diseases and con-
ditions [5,6].
I. Gingival diseases
II. Chronic periodontitis
III. Aggressive periodontitis
IV. Periodontitis as a manifestation of systemic diseases
V. Necrotizing periodontal diseases
VI. Abscesses of the periodontium
VII. Combined periodontic-endodontic lesions
VIII. Development or acquired deformities and conditions
Table 2. Guidelines for determining severity of periodontitis [8].
Slight (mild) Moderate Severe (advanced)
Probing depths >3 and <5 mm ≥5 and <7 mm ≥7 mm
Bleeding on
probing
Yes Yes Yes
Radiographic
bone loss
Up to 15% of root
length or ≥2 and
≤3 mm
16–30%
or >3 and
≤5 mm
>30%
or >5 mm
Clinical
attachment
loss
1–2 mm 3–4 mm ≥5 mm
Figure 1. A conceptual framework for chronic inflammation in periodontal tissues.
Environmental stressors, (a), and host responses, (b), contribute to periodontal chronic inflammation. Several cellular and molecular factors are responsible for an imbalance towards a
proinflammatory rather than anti-inflammatory immune response, that culminates into tissue injury. A bidirectional link with other systemic inflammatory diseases may operate and need
to be further investigated.
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chronic periodontitis is the presence of dysbiotic microbial
communities with potential for destructive inflammation.
However, in addition to periodontal microbiome influence,
smoke is also an important factor underlying the development
of periodontitis [15]. Other environmental stressors, either che-
mical or mechanical, that cause or promote oral inflammation,
could have a role in the development of chronic periodontitis.
This is still an unexplored research area and future investigation
is needed to identify other relevant etiological factors. In the
inside of the epithelial barrier, host genetic factors may predis-
pose to or protect from disease. Finally, systemic health status
and environmental factors that modify the host response have
also been implicated in chronic periodontitis [15]. Overall, both
environmental and host proinflammatory events favor a chronic
state of inflammation in the periodontal tissues, that lead to
injury and ultimately to bone resorption and tooth loss.
Extensive and detailed reviews on molecular and cellular
aspects of cytokines in periodontitis have been published
[13,14,16]. Cytokines might be divided into proinflammatory
or anti-inflammatory groups and imbalances between their
relative concentrations might lead to tissue destruction in
chronic periodontitis [13,14]. Other mediators such as lipid
mediators, growth factors, or chemokines have also an impor-
tant role in the perpetuation of inflammation [17,18].
Thus, chronic periodontitis is characterized by a persistent
inflammation of the periodontal tissues and is now consid-
ered a chronic noncommunicable disease that shares epide-
miological associations and underlying inflammatory
mechanisms with other systemic chronic inflammatory dis-
eases [18–20]. Several potential therapies, ranging from diet
to cytokines, capable of suppressing inflammation warrant
to for further investigations (Figure 1) [17,21,22]. Cytokine-
based treatment strategies have potential to improve both
chronic periodontitis and systemic health [23–26]. However,
given the complexity of cytokine networks, we believe that
it is fundamental to investigate further their role in the
chronic periodontitis disease process. The understanding of
the equilibrium between inflammatory (proinflammatory)
and suppressor (anti-inflammatory) responses, integrated
with both internal and external environmental factors,
could bring improved therapeutic interventions to modulate
host responses in chronic periodontitis and other chronic
inflammatory diseases.
Chronic periodontitis and systemic diseases
The evolution of healthcare in the last century has led to
improvement in the treatment of several diseases, leading
to an increased quality and life expectancy of patients.
Dental care and oral health is also a key factor involved in
the improvement of patients’ health. Indeed, in the recent
Tokyo Declaration on dental care and oral health for
healthy longevity [27], it was recognized that maintenance
of oral and dental health through life is a fundamental
factor for improved quality of life, helping to protect
against noncommunicable diseases and contributing
toward preventing the aggravation of such diseases.
Dental associations and other health professionals around
the world are encouraged to facilitate and enhance
coordination of activities to increase global awareness of
and contribute to the implementation of WHO’s Global
Action Plan for the Prevention and Control of
Noncommunicable Diseases 2013–2020 [27]. Periodontal
and systemic diseases share many features of inflammaging
and seem to be intertwined diseases [28,29].
Hence, the association between chronic periodontitis and
systemic illnesses may be bidirectional. One mechanism that
has been proposed for chronic periodontitis as a risk factor for
other systemic diseases, comprises systemic dissemination of
oral bacteria and inflammatory mediators, that are capable of
initiation and maintaining mechanisms associated with the
development of chronic systemic diseases [15]. Although sev-
eral systemic diseases (e.g. rheumatoid arthritis, renal diseases,
neurodegenerative diseases) show associations with chronic
periodontitis, in this review we will focus on the most preva-
lent noncommunicable diseases (cardiovascular, diabetes, can-
cer, and respiratory disease) and on pregnancy complications.
Moreover, we will also give emphases to the proinflammatory
common systemic mediators such as TNF-α, IL-1 and/or IL-6.
Interestingly, we have shown that these cytokines were
increased in gingival crevicular fluid in patients with chronic
periodontitis who did not have chronic systemic diseases
(Figure 2, chronic periodontitis at the center) [30].
Chronic periodontitis and cardiovascular disease
In a recent report of the Joint EFP/AAP workshop on period-
ontitis and systemic diseases, it was concluded that there is a
consistent and strong epidemiologic evidence that periodon-
titis imparts increased risk for future cardiovascular disease
[31]. It was also concluded that although in vitro, animal and
clinical studies do support interaction and biological mechan-
isms, still, well-design intervention trials to investigate the
impact of periodontal treatment on prevention of athero-
sclerotic cardiovascular disease, are a needed.
Vascular diseases are nowadays recognized to have a
strong local and systemic inflammatory pathogenic contribu-
tion. In atherosclerosis, along with the accumulation of cho-
lesterol debris on the artery wall, it is well established that
immune reactions and the participation cells and mediators
such as cytokines are implicated in the immunopathogenesis
of vascular diseases [32]. Among several factors, inflammatory
cytokines such as TNF-α, IL-1, and IL-6, have been shown to be
secreted by infiltrating leukocytes or by foam cells [33].
Parallelly, several investigations have demonstrated the impor-
tance of chronic infections in the atherosclerotic process,
namely by inducing a systemic inflammatory state and of
autoimmunity [33–36]. Some microbes can cause persistent
infection in the vessel wall and promote a proinflammatory
environment. Alternatively, the infection may also induce
autoimmunity against vascular cells and lead to atherosclero-
tic process [37]. In this context, chronic periodontitis and its
chronic inflammatory nature are associated with an increased
risk for cardiovascular disease [38]. Bacteremia and an inflam-
matory systemic state associated with chronic periodontitis
are important factors in the initiation of the endothelial lesion
as well as in the potentiation of the vascular wall inflammatory
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process [39–41]. The inflammatory process is also modulated
by proinflammatory cytokines such as TNF-α, IL-1, and IL-6
both in chronic periodontitis and in cardiovascular diseases
(Figure 2) [42]. Finally, some studies demonstrate a decrease
on systemic inflammatory biomarkers following periodontal
treatment and consequent possible benefit in the reduction
of cardiovascular risk [43–46]. However, while there is evi-
dence suggesting that periodontal therapy reduces systemic
inflammation and improves endothelial function, evidence on
its effects on cardiovascular events in long term is still limited
[43] and further studies are needed. Accordingly, a recent
publication of American Heart Association (AHA) stated that
although periodontal interventions result in a reduction in
systemic inflammation and endothelial dysfunction in short-
term studies, there is no evidence that they prevent athero-
sclerotic vascular disease or modify its outcomes [47].
Chronic periodontitis and diabetes
Association between chronic periodontitis and diabetes is
known for a long time, and it has a bidirectional association.
On one hand, diabetes is a modifier factor of chronic period-
ontitis, and, on the other hand, periodontitis is a complication
of diabetes [42,48,49]. Several studies showed a higher pre-
valence of periodontitis in diabetic patients, as well as a higher
periodontal disease severity in diabetic patients [50–52]. The
pathophysiological mechanisms involved appear to be a result
of chronic hyperglycemia resulting in decreased macrophage
and neutrophil function, accumulation of advanced glycosyla-
tion, and inflammation [53]. In contrast, there is also evidence
that concomitant presence of periodontitis impairs glycemic
control in diabetics, thereby increasing the risk of other com-
plications in diabetes [54–56]. Proinflammatory mediators,
such as TNF-α, IL-1, and IL-6 that are increased in both dis-
eases, represent a fundamental linkage (Figure 2) [52,53,57]. In
addition, the interindividual variability in both diseases is likely
to be influenced by genetic, epigenetic, and environmental
factors [52].
Periodontal treatment has been shown to be associated
with an improved glycemic control [58–60]. However, in
spite of a modest reduction in HbA1c observed as a result of
periodontal therapy in subjects with type 2 diabetes, there is
limited confidence in the conclusion due to a lack of
multicenter trials of sufficient sample size [60,61].
Chronic periodontitis and obstetric complications
Maternal infections associated with systemic inflammatory
states, where we may include chronic periodontitis, appear,
according to the literature, to contribute to a higher risk of
obstetric complications, such as premature births and low
birth weight. During pregnancy, the hormonal changes
increase vascular permeability in the gingival tissues that facil-
itate the diffusion of pathogenic microorganisms and their
Figure 2. Chronic periodontitis and some common systemic diseases.
Chronic periodontitis shares several associations with numerous chronic inflammatory diseases. Proinflammatory cytokines are, among other factors, important immune-related mediators
involved in the disease pathogenesis. Only the most common noncommunicable diseases and pregnancy complications were exemplified, although others (rheumatoid arthritis,
neurodegenerative disorders, etc.) exhibit also associations with chronic periodontitis. Illustration adapted medical elements from Servier Medical Art http://smart.servier.com/, with
permission to reproduce under the Creative Commons Attribution 3.0 Unported License https://creativecommons.org/licenses/by/3.0/
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products into the circulation and to the placenta. Here, they
may stimulate immune and inflammatory responses leading to
a high secretion of proinflammatory cytokine levels in the fetal
tissues and can lead to the premature rupture of membranes
and lead to uterine contractions, which in turn can cause
miscarriage or premature delivery [62]. Several meta-analysis
and systematic reviews reaffirm the association of periodonti-
tis with this complication [62–66]. One of the mechanisms
implicated may be mediated by elevated levels of proinflam-
matory cytokines (Figure 2) [62,67–69].
In addition, some studies have also demonstrated the pre-
sence of periodontal pathogenic microorganisms in the
amniotic fluid in women with periodontitis, and a correlation
between the severity of periodontitis and the risk of preterm
birth was found [62,70,71].
Several studies have sought to determine if there is a
benefit of periodontal treatment in women at risk for obstetric
complications, and although there is no consensus among the
various studies [72], it seems to be good practice to apply
preventive strategies in these women [73–75].
Chronic periodontitis and cancer
An increased risk of various neoplasms has been associated
with chronic periodontitis, namely oral cancers [76] and squa-
mous cell carcinoma [77]. However, a deficient control of
variables such as the history of tobacco and alcohol use, and
oral human papillomavirus infection limits these results [78].
There is also an increasing interest in the link between period-
ontal disease and overall cancer risk, with systemic inflamma-
tion serving as the focus for biological plausibility. In a recent
meta-analysis provided support for a positive association
between periodontal disease and risk of oral, lung, and pan-
creatic cancers. However, future studies should include suffi-
ciently large sample sizes, improved measurements for
periodontal disease, and thorough adjustment for smoking
and other risk factors [79]. Interestingly, currently, there is a
large body of evidence demonstrating that inflammation pro-
foundly affects all phases of cancer, from initiation at the
single-cell level, to early growth, progression, and dissemina-
tion [80,81]. Another emerging concept is that cancer, like
most diseases, is a systemic rather than a local disease.
Systemic inflammation in a functional relationship with energy
metabolism and genetic instability predisposes individuals to
cancer and regulates the neoplastic disease [80]. Cytokines
that are known to be elevated in chronic periodontitis, such
as TNF-α, IL-1, and IL-6, have been shown to promote breast
cancer and other cancers (Figure 2) [81,82].
Periodontitis and chronic respiratory diseases
There is emerging evidence for an association between
periodontal disease and pneumonia or chronic obstructive
pulmonary disease (COPD). The oral cavity is a reservoir for
pulmonary infection and there is some evidence that chronic
periodontitis may be associated with risk for pneumonia
[83–85]. It is likely that oral bacteria present in the dental
plaque are shed into saliva and are then aspirated into the
lower respiratory tract and the lungs to cause infection.
Additionally, cytokines and enzymes induced from the per-
iodontally inflamed tissues by the oral biofilm may also be
transferred into the lungs where they may stimulate local
inflammatory processes preceding colonization of pathogens
[86]. Several works demonstrated that application of strate-
gies to reduce oral microbial burden are associated with a
lower risk to develop pneumonia [83,87,88]. COPD is a group
of diseases characterized by the pathological limitation of
airflow in the airway, including chronic bronchitis, and
emphysema [89]. COPD and chronic periodontitis share
common risk factors such as cigarette smoke, age, and
poor socioeconomic status [90]. Moreover, some studies
supported an association between chronic periodontitis
and COPD although large-scale prospective epidemiological
studies are needed [78,91]. COPD and chronic periodontitis
share some proinflammatory mediators that may facilitate
disease progression of both pathologies (Figure 2) [90,92].
Interestingly, in a pilot trial, it has been shown that period-
ontal therapy in COPD patients with chronic periodontitis
may improve lung function and decrease the frequency of
COPD exacerbation [93].
Conclusion
Like to other human bodyborders, such as the gut, maintain-
ing a healthy oral mucosa may also have a positive impact on
the host health and might be preventive for other systemic
inflammatory disorders. Thus, it is important to encourage
further integrated studies to investigate the interrelationship
between inflammation, oral mucosal, and systemic chronic
diseases.
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